EP0806962A4 - Methods for the treatment of acid aspiration-induced acute lung injury - Google Patents

Methods for the treatment of acid aspiration-induced acute lung injury

Info

Publication number
EP0806962A4
EP0806962A4 EP96903731A EP96903731A EP0806962A4 EP 0806962 A4 EP0806962 A4 EP 0806962A4 EP 96903731 A EP96903731 A EP 96903731A EP 96903731 A EP96903731 A EP 96903731A EP 0806962 A4 EP0806962 A4 EP 0806962A4
Authority
EP
European Patent Office
Prior art keywords
treatment
methods
lung injury
acute lung
induced acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96903731A
Other languages
German (de)
French (fr)
Other versions
EP0806962A1 (en
Inventor
Virginia C Broaddus
Michael A Matthay
Hans G Folkesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP0806962A1 publication Critical patent/EP0806962A1/en
Publication of EP0806962A4 publication Critical patent/EP0806962A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
EP96903731A 1995-01-23 1996-01-23 Methods for the treatment of acid aspiration-induced acute lung injury Withdrawn EP0806962A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US454042 1990-09-10
US37707795A 1995-01-23 1995-01-23
US45404295A 1995-05-30 1995-05-30
PCT/US1996/001150 WO1996022785A1 (en) 1995-01-23 1996-01-23 Methods for the treatment of acid aspiration-induced acute lung injury
US377077 1999-08-19

Publications (2)

Publication Number Publication Date
EP0806962A1 EP0806962A1 (en) 1997-11-19
EP0806962A4 true EP0806962A4 (en) 2001-01-10

Family

ID=27007667

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96903731A Withdrawn EP0806962A4 (en) 1995-01-23 1996-01-23 Methods for the treatment of acid aspiration-induced acute lung injury

Country Status (5)

Country Link
EP (1) EP0806962A4 (en)
JP (1) JPH10512278A (en)
AU (1) AU4771696A (en)
CA (1) CA2211115A1 (en)
WO (1) WO1996022785A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049426A1 (en) * 1996-06-26 1997-12-31 Chugai Seiyaku Kabushiki Kaisha Remedies for acute pulmonary injuries due to indirect causes containing anti-il-8 antibody as the active ingredient
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
PT968291E (en) 1997-02-21 2004-06-30 Genentech Inc ANTIBODY AND POLYMER FRAGMENT CONJUGATES
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
AU2003299641C1 (en) 2002-12-16 2016-06-02 Cormorant Pharmaceuticals Ab Human monoclonal antibodies against interleukin 8 (IL-8)
SG11202005323SA (en) 2018-01-12 2020-07-29 Bristol Myers Squibb Co Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
A. BOYLAN ET AL.: "Evidence of a role for mesothelial cell-derived interleukin 8 in the pathogenesis of asbestos-induced pleurisy in rabbits.", JOURNAL OF CLINICAL INVESTIGATION, vol. 89, no. 4, 1992, New York, NY, USA, pages 1257 - 1267, XP000603440 *
A. HARADA ET AL.: "Essential involvement of interleukin-8 (IL-8) in acute inflammation.", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 56, no. 5, November 1994 (1994-11-01), New York, NY, USA, pages 559 - 564, XP000960610 *
G. PACE ET AL.: "Recent advances in the treatment of the acute respiratory distress syndrome.", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 5, no. 1, January 1995 (1995-01-01), London, GB, pages 23 - 30, XP000960612 *
H. FOLKESSON ET AL.: "Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms.", JOURNAL OF CLINICAL INVESTIGATION, vol. 96, no. 1, July 1995 (1995-07-01), New York, NY, USA, pages 107 - 116, XP000960674 *
M. MULLIGAN ET AL.: "Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody.", THE JOURNAL OF IMMUNOLOGY, vol. 150, no. 12, 15 June 1993 (1993-06-15), Baltimore, MD, USA, pages 5585 - 5595, XP000604925 *
R. ST.JOHN ET AL.: "Immunologic therapy for ARDS, septic shock, and multiple organ failure.", CHEST, vol. 103, no. 3, 1993, Chicago, IL, USA, pages 932 - 943, XP000603807 *
See also references of WO9622785A1 *
V. BROADDUS ET AL.: "Interleukin-8 is a major neutrophil chemotactic factor in pleural liquid of patients with empyema.", AMERICAN REVIEW OF RESPIRATORY DISEASES, vol. 146, no. 4, 1992, New York, NY, USA, pages 825 - 830, XP000603436 *
V. BROADDUS ET AL.: "Neutralization of IL-8 inhibits neutrophil influx in a rabbit model of endotoxin-induced pleurisy.", THE JOURNAL OF IMMUNOLOGY, vol. 152, no. 6, 15 March 1994 (1994-03-15), Baltimore, MD, USA, pages 2960 - 2967, XP000604775 *

Also Published As

Publication number Publication date
JPH10512278A (en) 1998-11-24
AU4771696A (en) 1996-08-14
WO1996022785A1 (en) 1996-08-01
EP0806962A1 (en) 1997-11-19
CA2211115A1 (en) 1996-08-01

Similar Documents

Publication Publication Date Title
GB9401520D0 (en) Treatment of poultry
HK1000697A1 (en) Use of droloxifene for the treatment of cardiovascular diseases
ZA957483B (en) Compounds and methods for the treatment of cancer
EP0831924A4 (en) Method of treatment for asthma
ZA966240B (en) Methods for treatment of allergic asthma.
EP1039883A4 (en) Methods for the treatment of apolipoprotein e related diseases
EP0806962A4 (en) Methods for the treatment of acid aspiration-induced acute lung injury
GB9509826D0 (en) Process for the preparation of imidazolutidine
HUP9900138A3 (en) Method for treatment of wood element
EP0755262A4 (en) Composition for the treatment of lung disease
AU6097394A (en) Method for the treatment of respiratory disease
GB2290452B (en) Shoe treatment apparatus
GB9507825D0 (en) Method of treatment
GB9415902D0 (en) Method of treatment
GB9407335D0 (en) Method of treatment
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
HU9701426D0 (en) Process for the preparation of acid chloride compounds
GB9414652D0 (en) Method of treatment
GB9605167D0 (en) Acid treatment process
GB9605166D0 (en) Acid treatment process
AU1829695A (en) Method of treatment of talc
IL118729A0 (en) Process for the preparation of 5-fluor-2-nitrobenzoic acid
EP0701984A3 (en) Process for the preparation of alkaliamides
GB9420524D0 (en) Method of treatment
GB9503200D0 (en) Methods of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FOLKESSON, HANS, G.

Inventor name: MATTHAY, MICHAEL, A.

Inventor name: BROADDUS, VIRGINIA, C.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

A4 Supplementary search report drawn up and despatched

Effective date: 20001124

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030801